Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E D Saad

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2015
Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agentsE D Saad, M Buyse
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 8, 2016
Response to the letter to the editor 'Reply to "Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents" by H. K. van Halteren'E D Saad, M Buyse
Revista Do Hospital Das Clinicas|January 1, 1996
[Evidence-based medicine]E D Saad, H Grunspun
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2008
Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely definedE D Saad, A Katz
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapyE D Saad, M Buyse
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2018
Avoiding the hazards of misinterpreting treatment effectsE D Saad, I F Tannock
Oncology (Williston Park, N.Y.)|February 28, 2001
Other fluorinated pyrimidines in the treatment of solid tumorsE D Saad, P M Hoff
Japanese Journal of Clinical Oncology|June 2, 2001
Case report: hand-foot syndrome induced by the oral fluoropyrimidine S-1S A Elasmar, E D Saad, P M Hoff
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 15, 2014
Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: does the sequence matter?J Bines, H Earl, A C Buzaid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2009
Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literatureE D Saad, A Katz, P M Hoff, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2015
Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agentsE D Saad, M Buyse
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 8, 2016
Response to the letter to the editor 'Reply to "Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents" by H. K. van Halteren'E D Saad, M Buyse
Revista Do Hospital Das Clinicas|January 1, 1996
[Evidence-based medicine]E D Saad, H Grunspun
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2008
Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely definedE D Saad, A Katz
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapyE D Saad, M Buyse
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2018
Avoiding the hazards of misinterpreting treatment effectsE D Saad, I F Tannock
Oncology (Williston Park, N.Y.)|February 28, 2001
Other fluorinated pyrimidines in the treatment of solid tumorsE D Saad, P M Hoff
Japanese Journal of Clinical Oncology|June 2, 2001
Case report: hand-foot syndrome induced by the oral fluoropyrimidine S-1S A Elasmar, E D Saad, P M Hoff
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 15, 2014
Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: does the sequence matter?J Bines, H Earl, A C Buzaid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2009
Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literatureE D Saad, A Katz, P M Hoff, et al.
Pageof 2